NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

NEU.AU NEUREN PHARMACEUTICALS LTD

Closed 05-21 16:12:00 AEST

20.73

-0.28

-1.33%

High21.19	Low20.70	Vol297.72K
Open20.87	D1 Closing21.01	Amplitude2.33%
Mkt Cap2.65B	Tradable Cap2.26B	Total Shares127.70M
T/O6.21M	T/O Rate0.27%	Tradable Shares109.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":20.73,"timestamp":1716271920000,"preClose":21.01,"halted":0,"volume":297723,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":109208662,"shares":127695676,"eps":1.201,"marketStatus":"Closed","change":-0.28,"latestTime":"05-21 16:12:00 AEST","open":20.87,"high":21.19,"low":20.7,"amount":6213761,"amplitude":0.023322,"askPrice":21,"askSize":15000,"bidPrice":20.72,"bidSize":6,"shortable":3,"etf":0,"ttmEps":1.201,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716336000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":21.01,"openAndCloseTimeList":[[1716249600000,1716271200000]],"volumeRatio":0.584019,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/NEU.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2435153276","title":"Guess which four ASX 300 shares were just re-rated by top brokers","url":"https://stock-news.laohu8.com/highlight/detail?id=2435153276","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2435153276?lang=en_us&edition=fundamental","pubTime":"2024-05-14 10:52","pubTimestamp":1715655159,"startTime":"0","endTime":"0","summary":"Four S&P/ASX 300 Index  shares were just re-rated by top brokers. One operates in the credit-impaired consumer debt segment. The second is a biopharmaceutical company. The third provides vehicle fleet leasing, fleet management, and diversified financial services. And the fourth is a New Zealand-based building and materials company. Any guesses?) The Fletcher Building share price is down 3.0% today at $2.79 a share. The stock has tumbled 35% over six months. Fortunately, Morgan Stanley believes the worst of the pain should be over. While the broker cut its price target by 23% to $2.84 a share, Morgan Stanley maintained its 'equal-weight' rating. Fletcher Buildings suspended its interim dividend payment for FY 2024 due to challenging trading conditions.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/14/guess-which-four-asx-300-shares-were-just-re-rated-by-top-brokers/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434200991","title":"Brokers name 3 ASX shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2434200991","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2434200991?lang=en_us&edition=fundamental","pubTime":"2024-05-10 12:25","pubTimestamp":1715315155,"startTime":"0","endTime":"0","summary":"It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/10/brokers-name-3-asx-shares-to-buy-now-69/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434036380","title":"Why Cettire, De Grey Mining, Life360, and Neuren shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2434036380","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2434036380?lang=en_us&edition=fundamental","pubTime":"2024-05-10 11:19","pubTimestamp":1715311182,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points. Four ASX shares that have failed to follow the market higher toda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/10/why-cettire-de-grey-mining-life360-and-neuren-shares-are-falling-today/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434020048","title":"Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2434020048","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434020048?lang=en_us&edition=fundamental","pubTime":"2024-05-10 08:12","pubTimestamp":1715299920,"startTime":"0","endTime":"0","summary":"0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research note on Acadia's partner, Neuren Pharmaceuticals, analyst David Stanton expects there will be around 2,250 patients who will have tried Daybue in the U.S. by end-FY 2024, up from 1,450 a year earlier. To achieve Acadia's guidance, 45% of patients diagnosed with Retts in the U.S. will have had to have tried Daybue, up from 29% at end-FY 2023. That doesn't appear to be \"high for an efficacious, well-covered drug with no other treatment options,\" he says. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434903143","title":"Why this high-flying ASX 200 healthcare stock just crashed 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434903143","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2434903143?lang=en_us&edition=fundamental","pubTime":"2024-05-09 11:49","pubTimestamp":1715226565,"startTime":"0","endTime":"0","summary":"Neuren has previously explained that seasonal effects negatively impacted 1Q FY24 sales.  These included refills that were due in January and actioned in December, prior to the holidays, and reduced Rett clinic days in January.  The company said discontinuations during Q1 were higher following a surge in new patient starts in the previous quarters.  Gross-to-net discounts were slightly higher in Q1, too.  Net patient additions have resumed, with increases in each of the past six weeks. The company said:   Approximately 25% of the 5,000 diagnosed Rett syndrome patients in the United States have initiated therapy.  Persistence on therapy continues to track more than 10% higher than the clinical trial experience, with 58% remaining on therapy after treatment for 9 months. 862 patients are currently on therapy.  What's next for this ASX healthcare stock?Neuren Pharmaceuticals said Acadia had made good progress on its international expansion for DAYBUE.  A New Drug Submission in Canada was ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/09/why-this-high-flying-asx-200-healthcare-stock-just-crashed-11/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434059038","title":"BUZZ-Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee","url":"https://stock-news.laohu8.com/highlight/detail?id=2434059038","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434059038?lang=en_us&edition=fundamental","pubTime":"2024-05-09 10:25","pubTimestamp":1715221500,"startTime":"0","endTime":"0","summary":"** Shares of Neuren Pharmaceuticals    fall as much as 10.6% to A$17.970, their lowest since Dec. 13, 2023   ** Stock posts its biggest intraday percentage decline since Feb. 28   ** Brain disorder drug maker says quarterly sales of co's drug licensed to U.S.-based Acadia Pharmaceuticals    came below expectations   ** Says ACAD's first quarter sales of co's drug DAYBUE were $75.9 mln, missing the forecast range of $76 mln to $82 mln   ** About 541,000 shares change hands, compared with the 30-day average volume of around 299,000   ** Stock down 19.5% YTD, based on last close","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434863770","title":"BRIEF-Neuren Pharmaceuticals Says Daybue Q1 2024 Net Sales $75.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2434863770","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434863770?lang=en_us&edition=fundamental","pubTime":"2024-05-09 08:15","pubTimestamp":1715213708,"startTime":"0","endTime":"0","summary":"May 9 (Reuters) - Neuren Pharmaceuticals Ltd   :   * DAYBUE Q1 2024 NET SALES US$75.9 MILLION   * DAYBUE FULL-YEAR GUIDANCE OF US$370-420 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432168721","title":"Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely","url":"https://stock-news.laohu8.com/highlight/detail?id=2432168721","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432168721?lang=en_us&edition=fundamental","pubTime":"2024-05-04 05:49","pubTimestamp":1714772980,"startTime":"0","endTime":"0","summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 10.8x Neuren Pharmaceuticals Limited ( ASX:NEU ) is a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/getting-in-cheap-on-neuren-pharmaceuticals-limited-asxneu-is","is_publish_highlight":false,"gpt_icon":0},{"id":"2432695404","title":"This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2432695404","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2432695404?lang=en_us&edition=fundamental","pubTime":"2024-05-02 09:00","pubTimestamp":1714611605,"startTime":"0","endTime":"0","summary":"The newly minted KP Rx Healthcare Opportunities Fund, managed by Hashan De Silva, comes from a strong pedigree.De Silva previously worked for Karst Peak, a spinoff from Tiger Management, run by legendary hedge fund manager Julian Robertson.Karst Peak founder Adam Leitzes is providing seed capital for KP Rx, following the playbook of Robertson, who seeded and mentored numerous ex-employees to run their own investment houses - affectionately known as \"Tiger cubs\".In addition to the seed capital from Karst Peak, KP Rx’s investors include some of Australia’s most successful healthcare entrepreneurs including Dr Chris Behrenbruch , Patrick Davies , Lou Panaccio  to name a few.The fund is not focused on GP clinics, hospitals, or healthcare services. Rather, it focuses on later-stage businesses, with De Silva describing KP Rx as a \"series A, B, or C investor, where we are coming in once a lot of the initial preclinical stuff has been done.\". Previous successful investments include now ASX-lis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","is_publish_highlight":false,"gpt_icon":0},{"id":"2432559328","title":"Backed by industry titans, this fundie is leveraging Australia's healthcare innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432559328","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2432559328?lang=en_us&edition=fundamental","pubTime":"2024-05-01 07:30","pubTimestamp":1714519806,"startTime":"0","endTime":"0","summary":"Name of the fund: KP Rx Healthcare Opportunities Fund. Description of strategy: A closed-ended VC fund designed to strategically invest in the most promising healthcare and health-tech companies across ANZ, targeting both private and early-stage public companies at the inflection point of valuation creation. Investment objective: Target net IRR of 20% over the life of the fund. Aim to return the majority of the capital 4-6 years into the fund's life, with a formal 10-year cap providing flexibility to unlock greater value by investing in companies that benefit from staying private longer.That’s the profile of Hashan De Silva, who is launching the KP Rx Healthcare Opportunities Fund. Whilst we wouldn't normally profile a fund manager's background and track record this way, it provides important context as it has attracted some of Australia’s most successful healthcare entrepreneurs who are backing the fund as investors, including;Much simpler ethics approvals and governance: In Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/backed-by-industry-titans-this-fundie-is-leveraging-australia-s-healthcare-innovation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/backed-by-industry-titans-this-fundie-is-leveraging-australia-s-healthcare-innovation","is_publish_highlight":false,"gpt_icon":0},{"id":"2430823027","title":"RS, RYAM and NMG are among materials movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2430823027","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430823027?lang=en_us&edition=fundamental","pubTime":"2024-04-26 02:16","pubTimestamp":1714068981,"startTime":"0","endTime":"0","summary":"More on Materials Sector  XLB Surges To The Sector-Performance Lead, More Upside Likely Albemarle remains the most heavily shorted materials stock in March Steel Dynamics, Dow among top materials picks ahead of Q1 earnings; Albemarle gets a Sell Seeking Alpha’s Quant Rating on Materials Select Sector SPDR ETF Dividend scorecard for Materials Select Sector SPDR ETF","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4094387-rs-ryam-and-nmg-are-among-materials-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2430230178","title":"NewMarket on Pace for Largest Percent Decrease Since February 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2430230178","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2430230178?lang=en_us&edition=fundamental","pubTime":"2024-04-26 02:16","pubTimestamp":1714068960,"startTime":"0","endTime":"0","summary":"NewMarket Corporation  is currently at $549.04, down $34.21 or 5.87%. --Would be lowest close since Jan. 2, 2024, when it closed at $547.69. --On pace for largest percent decrease since Feb. 3, 2022, when it fell 11.11%. --Currently down three consecutive days; down 6.71% over this period. --Down 13.49% month-to-date; on pace for worst month since Feb. 2012, when it fell 15.62%. --Down 14.73% from its all-time closing high of $643.89 on March 1, 2024. --Up 38.81% from 52 weeks ago , when it closed at $395.52. --Up 40.84% from its 52-week closing low of $389.82 on May 31, 2023. --Traded as low as $542.73; lowest intraday level since Jan. 3, 2024, when it hit $542.32. --Down 6.95% at today's intraday low; largest intraday percent decrease since Feb. 3, 2022, when it fell as much as 11.6%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429129081","title":"Where are they now? The 10 biggest gainers in the ASX 200 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2429129081","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429129081?lang=en_us&edition=fundamental","pubTime":"2024-04-24 07:23","pubTimestamp":1713914586,"startTime":"0","endTime":"0","summary":"There’s a saying which has been popularised in movies like Mad Max: “One day you’re cock of the walk, the next, you’re a feather duster”. It’s the equivalent of ‘past performance is no reliable indicator of future performance’ which is imprinted in my brain from years working in a bank, let alone with fund managers today.If there was a year to worry about the so-called ‘cock of the walks’, 2023 would probably stand high with AI fuelling the extraordinary success of the Magnificent Seven. Despite that, many contributors to Livewire have suggested there is more to come – at least for the time being.But while that might cover off the biggest hitters globally, what about closer to home?It’s only a few months ago, but do you remember who the biggest gainers on the ASX200 were in 2023?My colleague Kerry Sunhas crunched the numbers for me and pulled the 10 biggest gainers as at 29 December 2023.The 10 biggest gainers of the ASX200 as at end 2023","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/where-are-they-now-the-10-biggest-gainers-in-the-asx-200-last-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/where-are-they-now-the-10-biggest-gainers-in-the-asx-200-last-year","is_publish_highlight":false,"gpt_icon":0},{"id":"2429044181","title":"BRIEF-Neuren Pharmaceuticals Says Trofinetide New Drug Submission For Rett Syndrome Accepted For Priority Review By Health Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2429044181","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2429044181?lang=en_us&edition=fundamental","pubTime":"2024-04-23 09:22","pubTimestamp":1713835367,"startTime":"0","endTime":"0","summary":"April 23 (Reuters) - Neuren Pharmaceuticals Ltd :   * TROFINETIDE NEW DRUG SUBMISSION FOR RETT SYNDROME ACCEPTED FOR PRIORITY REVIEW BY HEALTH CANADAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426477456","title":"How your #1 stock tips fared in Q1 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2426477456","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2426477456?lang=en_us&edition=fundamental","pubTime":"2024-04-11 10:00","pubTimestamp":1712800829,"startTime":"0","endTime":"0","summary":"As the market continues to confound by staying at record highs, some of the top local sectors in the first quarter were Technology, Real Estate and Financials. Two of these featured among the stocks that you, our valued readers, named as your top tips for 2024 in our Outlook Series reader survey .In the following table, we recap the full list of companies you selected and weigh their performance in the first quarter of 2024.Read on to find out which names across the Commodities, Healthcare  and Consumer Discretionary sectors topped the table – and also some of those that lagged.For the top five performers, we also delve into some of the most recent professional investor commentary featured on Livewire Markets.This demand is spurred by the growing realisation that developed nations need to embrace nuclear fuel if they’re to come anywhere near hitting their aggressive carbon emission reduction targets. That’s why we saw the US, Canada, UK, and Japan among 22 nations that committed to tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/how-your-1-stock-tips-fared-in-q1-2024","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/how-your-1-stock-tips-fared-in-q1-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2424671079","title":"3 ASX shares to help turn $100,000 into $1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2424671079","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2424671079?lang=en_us&edition=fundamental","pubTime":"2024-04-03 03:00","pubTimestamp":1712084400,"startTime":"0","endTime":"0","summary":"Turning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers if they use ASX shares and compounding to their advantage. Allow me to introduce you to three stocks that I reckon could do the trick: Temporary glitch, with long-term tailwinds still there Johns Lyng Group Ltd  is an insurance claims repairer that has been a favourite of professional investors for years now. And why not?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/03/3-asx-shares-to-help-turn-100000-into-1-million/","is_publish_highlight":false,"gpt_icon":0},{"id":"2424741912","title":"Top ASX shares to buy in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2424741912","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2424741912?lang=en_us&edition=fundamental","pubTime":"2024-04-01 01:00","pubTimestamp":1711904400,"startTime":"0","endTime":"0","summary":"If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index so far in 2024, fear not!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/01/top-asx-shares-to-buy-in-april-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2422794963","title":"1 secretly cheap ASX 200 stock I'm buying for the long run","url":"https://stock-news.laohu8.com/highlight/detail?id=2422794963","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2422794963?lang=en_us&edition=fundamental","pubTime":"2024-03-28 01:30","pubTimestamp":1711560600,"startTime":"0","endTime":"0","summary":"When an S&P/ASX 200 Index  stock outperforms all and sundry one year but then suddenly dips, you need to at least check out what's happening. Neuren Pharmaceuticals Ltd  was the highest climber in the ASX 200 last year, gaining an insane 214% over the calendar year. But a reality check has been delivered for investors this year, with an 18.6% tumble so far. So what's doing?Is this a bargain just waiting to be bought?Why has Neuren become a cheap ASX stock?So is this a value trap or a golden opportunity to buy into a fast-growing company for dirt cheap?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/28/1-secretly-cheap-asx-200-stock-im-buying-for-the-long-run/","is_publish_highlight":false,"gpt_icon":0},{"id":"2421028121","title":"3 ASX stocks boasting better margins than Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2421028121","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2421028121?lang=en_us&edition=fundamental","pubTime":"2024-03-21 23:30","pubTimestamp":1711035000,"startTime":"0","endTime":"0","summary":"The green graphics card giant is making a motza. But did you know some ASX companies have even bigger profit margins than Nvidia Corp ?Masterfully riding the AI wave, Nvidia looks like the Kelly Slater of computer hardware. The insatiable hunger for AI-enabling chips is fattening the technology company's profits. For 12 months ended January 2024, this A$3.4 trillion business pulled a 48.8% net margin.I'm talking margin monsters like Nvidia on our local ASX bourse.There are 43 ASX-listed stocks with superior margins to Nvidia. However, I wouldn't count some of these due to quirky accounting practices. Still, if thick profit margins are your jam, plenty of options exist.67% net margin: Any business that collects a royalty on something usually operates on high margins. There are minimal costs to eat away at the revenue gathered from sales. Deterra Royalties Ltd  is a locally-listed company relishing in this situation.In the 12 months ended 31 December 2023, Neuren reached $231.9 million i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/22/3-asx-stocks-boasting-better-margins-than-nvidia/","is_publish_highlight":false,"gpt_icon":0},{"id":"2420284943","title":"The best ASX shares to invest $500 in right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2420284943","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2420284943?lang=en_us&edition=fundamental","pubTime":"2024-03-19 03:30","pubTimestamp":1710790200,"startTime":"0","endTime":"0","summary":"Market is telling you that it's exciting about its future and that it's essential in AI. \"Half of its revenue is from NSW and ACT — hu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/19/the-best-asx-shares-to-invest-500-in-right-now/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurenpharma.com","stockEarnings":[{"period":"1week","weight":0.1023},{"period":"1month","weight":0.1105},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.3905},{"period":"1year","weight":0.4672},{"period":"ytd","weight":-0.1586}],"compareEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":0.0615},{"period":"3month","weight":0.0878},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.315789,"avgChangeRate":-0.052499},{"month":2,"riseRate":0.35,"avgChangeRate":-0.043889},{"month":3,"riseRate":0.5,"avgChangeRate":0.37497},{"month":4,"riseRate":0.4,"avgChangeRate":0.010585},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.045376},{"month":6,"riseRate":0.684211,"avgChangeRate":0.111382},{"month":7,"riseRate":0.315789,"avgChangeRate":-0.047153},{"month":8,"riseRate":0.421053,"avgChangeRate":0.013904},{"month":9,"riseRate":0.631579,"avgChangeRate":0.130929},{"month":10,"riseRate":0.631579,"avgChangeRate":0.084928},{"month":11,"riseRate":0.473684,"avgChangeRate":0.038496},{"month":12,"riseRate":0.315789,"avgChangeRate":0.025797}],"exchange":"ASX","name":"NEUREN PHARMACEUTICALS LTD","nameEN":"NEUREN PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUREN PHARMACEUTICALS LTD,NEU.AU,NEUREN PHARMACEUTICALS LTD股票,NEUREN PHARMACEUTICALS LTD股票老虎,NEUREN PHARMACEUTICALS LTD股票老虎国际,NEUREN PHARMACEUTICALS LTD行情,NEUREN PHARMACEUTICALS LTD股票行情,NEUREN PHARMACEUTICALS LTD股价,NEUREN PHARMACEUTICALS LTD股市,NEUREN PHARMACEUTICALS LTD股票价格,NEUREN PHARMACEUTICALS LTD股票交易,NEUREN PHARMACEUTICALS LTD股票购买,NEUREN PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction